Abstracts Archive - Page 111 of 2605 - ACR Meeting Abstracts

Abstract Number: 1255 • ACR Convergence 2025
Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience
Reena Yaman¹, Lisa Balistreri², Maximiliano Diaz Menindez³, Sehreen Mumtaz¹, Megan Sullivan³, Alexander Hochwald¹ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Lee Health, Cape Coral, FL, ³Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Pulmonary disease is present in most sarcoidosis cases with up to 10% of patients progressing to advanced lung disease.1 Pulmonary sarcoidosis accounted for 2.5%…
Abstract Number: 1267 • ACR Convergence 2025
Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
Leah Santacroce¹, Misti Paudel² and Daniel Solomon³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Newton, MA
Background/Purpose: Patient Reported Outcomes (PROs) collected via a mobile health application (App) can provide valuable insight into the health of patients with Rheumatoid Arthritis (RA).…
Abstract Number: 1264 • ACR Convergence 2025
Breaking the Veil: Preliminary Findings for a Qualitative Analysis of Rheumatoid Arthritis Patient Perspectives on Physical Activity and Mental Healt
Daniel Garcia¹, Vanessa Madrigal², Noelia Hernandez³, Alisha Akinsete⁴, Iris Navarro-Millan⁵, Ileana Vazquez Otero⁶, Ariana Gonzalez Melendez⁷, Sarah Young⁸ and Monika Safford², ¹Weill Cornell, Brooklyn, NY, ²Weill Cornell Medicine, New York, ³Weill Cornell Medicine, New York, NY, ⁴Weill Cornell Medical Center, New York, NY, ⁵Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY, ⁶Clinica Reuviva, San Juan, PR, ⁷Ponce Health Sciences, San Juan, PR, ⁸Weill Cornell Medicine, Johnson City, NY
Background/Purpose: Approximately 1.3 million Americans have rheumatoid arthritis (RA)1. Up to 83% of people with chronic pain, the hallmark symptom of RA also experience anxiety…
Abstract Number: 1354 • ACR Convergence 2025
Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Hongtao Jin, Huifang Guo, Yuxiang Han and Meng Ding, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic)
Background/Purpose: Joint swelling and tenderness are major symptoms of rheumatoid arthritis (RA). This post-hoc analysis evaluated the effect of ivarmacitinib (SHR0302), a selective Janus kinase…
Abstract Number: 1075 • ACR Convergence 2025
Racial Differences in Management and Clinical Outcomes of Giant-Cell Arteritis: A Real-World Propensity-Matched Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Fabian Rodriguez Quinonez⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Einstein Medical Center Philadelphia, Philadelphia, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Giant-cell arteritis (GCA) is usually described in people of Northern-European ancestry, and little is known about outcomes in Black and Hispanic (B-His) patients. Using…
Abstract Number: 1334 • ACR Convergence 2025
Cardiac Biomarkers and Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
manon lesturgie¹, Fiona Oudart¹, Anne Cauvet², Virginie Gonzalez², Bruno Fautrel³, Arnaud Constantin⁴, Nathalie Rincheval⁵, Yannick Allanore⁶ and Jérôme Avouac⁷, ¹INSERM U¹⁰¹⁶, Paris, France, ²INSERMU¹⁰¹⁶, Paris, France, ³Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ⁴Hôpital Pierre-Paul Riquet, CHU Purpan, Toulouse, France, ⁵Institut de Recherche Clinique EA²⁴¹⁵, Université de Montpellier, Département de Statistiques, Montpellier, France, ⁶Université Paris Cité, Paris, France, ⁷Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with rheumatoid arthritis (RA) experience premature mortality, largely due to cardiovascular (CV) disease. The increased CV risk is due to both the underlying…
Abstract Number: 1320 • ACR Convergence 2025
Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
Noah Frechette¹, Elena myasoedova¹, Iqra Javed¹, Roslin George¹, Sara Achenbach² and Cynthia Crowson³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Venous thromboembolism (VTE) is more common in patients with rheumatoid arthritis (RA) and can present as deep vein thrombosis (DVT) or pulmonary embolism (PE).…
Abstract Number: 1240 • ACR Convergence 2025
Serum Olink Proteomics Identifies Novel Mediators of Pain in Lupus Nephritis Patients Without Extrarenal Clinical Activity
Sarah Keegan¹, Philip Carlucci², Peter Izmirly³, Erin Carter⁴, Sanchit Sanyal⁵, Brooke Cohen⁶, Jasmine Shwetar⁷, Katie Preisinger⁸, Devyn Zaminski⁶, Kristina Deonaraine⁶, Mala Masson⁹, Andrea Fava¹⁰, Judith James¹¹, Rufei Lu¹¹, Wade DeJager¹², Chaim Putterman¹³, Michael Belmont¹⁴, Richard Furie¹⁵, Maria Dall'Era¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, Jennifer Anolik¹⁹, David Wofsy²⁰, Jennifer Barnas²¹, Nir Hacohen²², Robert Clancy²³, Joel Guthridge¹¹, Brad Rovin²⁴, Michelle Petri²⁵, Jill Buyon³ and Kelly Ruggles²⁶, ¹NYU Langone, New York, ²New York University School of Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶NYU Langone, NYC, ⁷New York University School of Medicine, Department of Medicine, New York, ⁸NYU Langone, NYU Langone, ⁹NYU Langone Medical Center- Division of Rheumatology, New York, NY, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Oklahoma Medical Research Foundation, Oklahoma City, ¹³Albert Einstein College of Medicine, Safed, Israel, ¹⁴NYU Langone Health, New York, NY, ¹⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ¹⁶Division of Rheumatology, University of California, San Francisco, CA, ¹⁷Medical University of South Carolina, Johns Island, SC, ¹⁸UC San Diego, La Jolla, CA, ¹⁹University of Rochester Medical Center, Rochester, NY, ²⁰University of California San Francisco, SF, CA, ²¹University of Rochester, Rochester, NY, ²²Broad Institute of MIT Harvard, Cambridge, MA, ²³Columbia University, New York, NY, ²⁴The Ohio State University, Columbus, OH, ²⁵Johns Hopkins University School of Medicine, Timonium, MD, ²⁶NYU Grossman School of Medicine, Brooklyn, NY
Background/Purpose: For patients with lupus nephritis, active disease can be solely renal or include a range of extrarenal signs, such as arthritis or serositis, that…
Abstract Number: 1205 • ACR Convergence 2025
Real-time MRI for assessment of swallowing impairment in inclusion body myositis and oculopharyngeal muscular dystrophy.
Rachel Zeng¹, Anke Rietveld², Omar Al-Bourini¹, Rosemarie HMJM Kroon², Arno Olthoff¹, Matthias Weidenmüller¹, Per-Ole Carstens¹, Isabel Kommerell¹, Saskia G Schütz¹, Corinne GC Horlings³, Johanna G Kalf³, Bert JM de Swart³, Baziel GM van Engelen², Tim Friede¹, Sabine Hofer¹, Jens Frahm⁴, Ali Seif Amir Hosseini¹, Jens Schmidt⁵ and Christiaan GJ Saris², ¹University Medical Center Göttingen, Göttingen, Germany, ²Radboudumc Research Institute for Medical Innovation, Nijmegen, Netherlands, ³Radboudumc Research Institute for Medical Innovation, Nijmegen, Germany, ⁴Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany, ⁵Immanuel University Hospital Rüdersdorf, Brandenburg Medical School, Rüdersdorf bei Berlin, Germany
Background/Purpose: Swallowing dysfunction -dysphagia- is a frequent and debilitating symptom in neuromuscular disorders, leading to malnutrition, cachexia, aspiration pneumonia and death. Identification of the underlying…
Abstract Number: 1219 • ACR Convergence 2025
Anti-Ro52 Antibody Identifies Patients with More Severe Lung disease among Patients with Idiopathic Inflammatory Myopathy
Vasiliki Syrmou¹, Ioannis Alexiou², Christos Liaskos³, Eleni Patrikiou³, THEODORA SIMOPOULOU⁴, Christina Katsiari⁵ and Dimitrios Bogdanos⁶, ¹University General Hospital of Larisa, University of Thessaly, Faculty of Medicine, Larisa, Greece, ²University General Hospital of Larisa, Larissa, Greece, ³University of Thessaly, Faculty of Medicine, Larisa, Greece, ⁴University Hospital of Larissa, Greece, Larissa, Greece, ⁵University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, ⁶Professor, Larissa, Greece
Background/Purpose: Anti-Ro52 antibodies are commonly detected in idiopathic inflammatory myopathies (IIMs), yet their clinical significance remains incompletely defined. There is evidence that it coexists with…
Abstract Number: 1025 • ACR Convergence 2025
Association Between Rural-Urban Clinics and the Management of Adult Rheumatoid Arthritis in the United States
Megan Lorenz, Paxten Wahlund, Henry Elsenpeter, Abe Sahmoun and James Beal, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) improve symptom management and outcomes in rheumatoid arthritis (RA). While residence may influence management strategies and access to care,…
Abstract Number: 1273 • ACR Convergence 2025
Effectiveness of IV Cyclophosphamide and Mycophenolate Mofetil in the Treatment of Pediatric Systemic Lupus Erythematosus with Lupus Nephritis
adrienne katrin guiang-valerio, University of Santo Tomas Hospital, Mandaluyong, National Capital Region, Philippines
Background/Purpose: Lupus nephritis (LN) is more common in children (occurs in 50-82%) compared to adults. Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are both treatment options…
Abstract Number: 1326 • ACR Convergence 2025
Association Between Physical Function and Nutritional Status in Rheumatoid Arthritis Patients
Yasumori Sobue¹, Mochihito Suzuki², Yoshifumi Ohashi³, Shuji Asai² and Shiro Imagama², ¹Sobue Orthopedic Clinic Yatomi, Aichi, Japan, ²Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Aichi Medical University, Graduate School of Medicine, Aichi, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that primarily affects the joints but also has substantial implications for physical function. Persistent inflammation may…
Abstract Number: 1356 • ACR Convergence 2025
Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Jonathan Kay¹, Eugen feist², Ernest Choy³, Joerg Kaufmann⁴, Ernest Wong⁵, Hector Corominas⁶, René-Marc Flipo⁷, Jérôme Avouac⁸, María América López Lasanta⁹, Joelle Monnet¹⁰, Peter Baker¹¹, Maria Romanova Michailidi¹², Fabrizio Dolfi¹¹ and Graziella Pourcel¹³, ¹UMass Chan Medical School, Worcester, MA, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ⁴NA, Ludwigsfelde, Germany, ⁵Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁶Hospital de Sant Pau, Barcelona, Spain, ⁷Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁸Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁹Hospital Universitario Vall d´Hebron, Barcelona, Spain, ¹⁰Fresenius Kabi SwissBioSim, Eysins, Switzerland, ¹¹Fresenius Kabi Biopharma, Eysins, Switzerland, ¹²University of Geneva, Eysins, Switzerland, ¹³Fresenius Kabi Biopharma, Eyzins, France
Background/Purpose: Although most healthcare professionals are convinced of the quality, safety, and favorable economic impact of biosimilars, their routine use is not yet widespread. MSB11456…
Abstract Number: 1281 • ACR Convergence 2025
Ethnic Disparities in Mental Health Screening, Diagnoses, and Outcomes in Patients with Childhood-Onset Systemic Lupus Erythematosus
Alicia Tran¹, Indrani Das², Zhaoyu Ding³, Daniela Dominguez⁴, Sefi Kronenberg⁵, Lawrence Ng⁶, Alene Toulany¹, Gwyneth Zai⁷, Deborah Levy¹, Andrea Knight⁸ and Linda Hiraki¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³SickKids Research Institute, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, Canada, ⁵Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON, Canada, ⁶The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁷Centre for Addiction & Mental Health, Toronto, ON, Canada, ⁸Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) face higher risks of depression and anxiety compared to healthy peers. In 2022, standardized mental health (MH)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].